AbbVie is expected to release a hepatitis C drug that could compete with the costly, but effective Sovalid and Harvoni treatments from Gilead Science, according to Reuters report.
On Nov. 4, Boston Scientific stock traded at between $13.19 and $13.30 per share, with a 52-week range of $11.10 to $14.08, according to a Jutia Group report.
Cantel Medical acquired International Medical Service S.r.l., a manufacturer of disinfectants used in automated endoscope reprocessors. IMS will be integrated into Cantel Medical’s Medivators business unit.
EndoChoice is planning a $100 million to $150 million NASDAQ initial public offering for 2015. The company has yet to file a prospectus for the IPO.
Salix Pharmaceuticals shares have been given an average rating of “buy” from multiple brokerages, according to a Sleek Money report.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.
More articles on gastroenterology:
Top GI code facility payments: 2015 vs. 2014
CMS delays review of lower GI/endoscopy codes
How to impact revenue and profitability in the changing GI endoscopy market
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
